Therapy of Lymphoma/Leukemia with Monoclonal Antibodies

Effie W Petersdorf

Genetic Mechanisms of Survivorship Disparities after Unrelated HCT

Leukaemia

Talya Salz

Do cardiovascular risk factors modify the cardiotoxicity of lymphoma treatments?

Non-Hodgkin lymphoma Hodgkin lymphoma

Martha Lassiter

2012 Tata Memorial Hospital Bone Marrow Transplant Program in Kolkata, India

Hodgkin lymphoma

Hematology and hematologic malignancies

Stanley R. Riddell

Targeted therapy of B cell malignances with CAR-T cells of defined composition

Non-Hodgkin lymphoma Leukaemia

Wilburn E. Reddick

ALL therapy and developing brains: MRI measures, genetic factors and cognition

Leukaemia

Pediatric oncology or childhood cancer

Martha Lassiter

Duke University Nursing Oncology Training Exchange with Tata Memorial Hospital

Hodgkin lymphoma Leukaemia Non-Hodgkin lymphoma

Catherine Ju-Ying Wu

(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL

Leukaemia

Manoj Menon

AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)

Hodgkin lymphoma

Hematology and hematologic malignancies

Theodore S Jardetzky

Inhibitors of the Epstein-Barr Virus Entry Machinery

Hodgkin lymphoma Non-Hodgkin lymphoma